Neuralstem, Inc. (NASDAQ:CUR) saw a significant increase in short interest in the month of December. As of December 15th, there was short interest totalling 1,413,759 shares, an increase of 136.4% from the November 30th total of 598,032 shares. Approximately 11.3% of the company’s shares are sold short. Based on an average daily volume of 6,510,771 shares, the days-to-cover ratio is presently 0.2 days.

Shares of Neuralstem (NASDAQ:CUR) opened at $2.03 on Wednesday. Neuralstem has a 12-month low of $0.88 and a 12-month high of $6.60. The firm has a market capitalization of $30.75, a price-to-earnings ratio of -1.22 and a beta of 1.63.

Several institutional investors have recently bought and sold shares of CUR. Blair William & Co. IL increased its position in shares of Neuralstem by 171.0% during the second quarter. Blair William & Co. IL now owns 87,343 shares of the company’s stock worth $506,000 after acquiring an additional 55,115 shares during the period. Vanguard Group Inc. increased its position in shares of Neuralstem by 1.1% during the second quarter. Vanguard Group Inc. now owns 345,346 shares of the company’s stock worth $2,000,000 after acquiring an additional 3,853 shares during the period. Finally, National Asset Management Inc. increased its position in shares of Neuralstem by 9.2% during the second quarter. National Asset Management Inc. now owns 22,985 shares of the company’s stock worth $134,000 after acquiring an additional 1,937 shares during the period. 7.05% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This piece was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another site, it was illegally copied and republished in violation of US & international copyright law. The legal version of this piece can be read at https://www.thecerbatgem.com/2018/01/03/neuralstem-inc-cur-short-interest-update.html.

Neuralstem Company Profile

Neuralstem, Inc (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform.

Receive News & Ratings for Neuralstem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuralstem and related companies with MarketBeat.com's FREE daily email newsletter.